144 related articles for article (PubMed ID: 23788873)
1. Effects of zoledronic acid and ibandronic acid on renal functions and calcium, phosphorus and alkaline phosphatase levels in breast cancer patients with bone metastases: a retrospective analysis.
Fidan E; Yildiz B; Kavgaci H; Ozdemir F; Aydin F
Contemp Oncol (Pozn); 2012; 16(2):176-8. PubMed ID: 23788873
[TBL] [Abstract][Full Text] [Related]
2. Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
McKeage K; Plosker GL
Pharmacoeconomics; 2008; 26(3):251-68. PubMed ID: 18282018
[TBL] [Abstract][Full Text] [Related]
3. Ibandronic acid: a review of its use in the treatment of bone metastases of breast cancer.
McCormack PL; Plosker GL
Drugs; 2006; 66(5):711-28. PubMed ID: 16620148
[TBL] [Abstract][Full Text] [Related]
4. Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 Years.
Guarneri V; Donati S; Nicolini M; Giovannelli S; D'Amico R; Conte PF
Oncologist; 2005; 10(10):842-8. PubMed ID: 16314295
[TBL] [Abstract][Full Text] [Related]
5. Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases.
Body JJ; Lichinitser M; Tjulandin S; Garnero P; Bergström B
Ann Oncol; 2007 Jul; 18(7):1165-71. PubMed ID: 17442659
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial.
Pecherstorfer M; Rivkin S; Body JJ; Diel I; Bergström B
Clin Drug Investig; 2006; 26(6):315-22. PubMed ID: 17163265
[TBL] [Abstract][Full Text] [Related]
7. Renal safety of zoledronic acid administration beyond 24 months in breast cancer patients with bone metastases.
Dincer M; Altundag K; Harputluoglu H; Aksoy S; Cengiz M; Gullu I
Med Oncol; 2008; 25(3):356-9. PubMed ID: 18196480
[TBL] [Abstract][Full Text] [Related]
8. Renal safety of intravenous ibandronic Acid in breast cancer patients with metastatic bone disease.
Lyubimova NV; Kushlinsky NE; Lichinitser MR; Schlosser K
Clin Drug Investig; 2003; 23(11):707-16. PubMed ID: 17536884
[TBL] [Abstract][Full Text] [Related]
9. Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice.
Sieber P; Lardelli P; Kraenzlin CA; Kraenzlin ME; Meier C
Clin Drug Investig; 2013 Feb; 33(2):117-22. PubMed ID: 23184667
[TBL] [Abstract][Full Text] [Related]
10. Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review.
Diel IJ; Weide R; Köppler H; Antràs L; Smith M; Green J; Wintfeld N; Neary M; Duh MS
Support Care Cancer; 2009 Jun; 17(6):719-25. PubMed ID: 19089462
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
12. Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307.
Gralow JR; Barlow WE; Paterson AHG; M'iao JL; Lew DL; Stopeck AT; Hayes DF; Hershman DL; Schubert MM; Clemons M; Van Poznak CH; Dees EC; Ingle JN; Falkson CI; Elias AD; Messino MJ; Margolis JH; Dakhil SR; Chew HK; Dammann KZ; Abrams JS; Livingston RB; Hortobagyi GN
J Natl Cancer Inst; 2020 Jul; 112(7):698-707. PubMed ID: 31693129
[TBL] [Abstract][Full Text] [Related]
13. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.
Himelstein AL; Foster JC; Khatcheressian JL; Roberts JD; Seisler DK; Novotny PJ; Qin R; Go RS; Grubbs SS; O'Connor T; Velasco MR; Weckstein D; O'Mara A; Loprinzi CL; Shapiro CL
JAMA; 2017 Jan; 317(1):48-58. PubMed ID: 28030702
[TBL] [Abstract][Full Text] [Related]
14. Zoledronic acid: a review of its use in patients with advanced cancer.
Perry CM; Figgitt DP
Drugs; 2004; 64(11):1197-211. PubMed ID: 15161327
[TBL] [Abstract][Full Text] [Related]
15. Zoledronic acid is more efficient than ibandronic acid in the treatment of symptomatic bone marrow lesions of the knee.
Müller F; Appelt KA; Meier C; Suhm N
Knee Surg Sports Traumatol Arthrosc; 2020 Feb; 28(2):408-417. PubMed ID: 31273410
[TBL] [Abstract][Full Text] [Related]
16. Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone-only metastases.
Niikura N; Liu J; Hayashi N; Palla SL; Tokuda Y; Hortobagyi GN; Ueno NT; Theriault RL
Cancer; 2012 Apr; 118(8):2039-47. PubMed ID: 22139648
[TBL] [Abstract][Full Text] [Related]
17. Zoledronic acid treatment at home: safety data from an observational prospective trial.
Tassinari D; Poggi B; Nicoletti S; Fantini M; Tamburini E; Possenti C; Sartori S
J Palliat Med; 2007 Apr; 10(2):352-8. PubMed ID: 17472506
[TBL] [Abstract][Full Text] [Related]
18. An audit to determine the time taken to administer intravenous bisphosphonate infusions in patients diagnosed with metastatic breast cancer to bone in a hospital setting.
Barrett-Lee P; Bloomfield D; Dougherty L; Harries M; Laing R; Patel H; Walker M
Curr Med Res Opin; 2007 Jul; 23(7):1575-82. PubMed ID: 17559749
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial.
Amadori D; Aglietta M; Alessi B; Gianni L; Ibrahim T; Farina G; Gaion F; Bertoldo F; Santini D; Rondena R; Bogani P; Ripamonti CI
Lancet Oncol; 2013 Jun; 14(7):663-70. PubMed ID: 23684411
[TBL] [Abstract][Full Text] [Related]
20. Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer.
Francini F; Pascucci A; Bargagli G; Francini E; Conca R; Miano ST; Martellucci I; Migali C; Gotti G; Fiaschi AI; Cozzolino A; Petrioli R
Int J Clin Oncol; 2011 Jun; 16(3):264-9. PubMed ID: 21240683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
